• 24 September 2020
    Axonics® Provides Update on Inter Partes Review Proceedings

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has made the decision to institute a review regarding the validity of six Medtronic patents that Axonics is contesting.

    On March 16, Axonics filed seven inter partes review (IPR) petitions contesting the validity of certain Medtronic patents. The PTAB has instituted the IPR petitions on U.S. Patent Nos. 7,774,069; 8,036,756; 8,457,758; 8,626,314; 8,738,148; and 9,821,112. The IPR petition for U.S. Patent No. 9,463,324 was not instituted.

    Raymond W. Cohen, Axonics CEO, said, “We are pleased that the PTAB has instituted IPR petitions on these patents, which means that Axonics has demonstrated that there is a ‘reasonable likelihood’ that at least some, if not all, of the claims in each of these Medtronic patents are invalid.”

    Cohen continued, “Since its founding, Axonics has focused on innovation and developing best-in-class SNM solutions for patients. We have made significant investments in R&D and created a strong portfolio of intellectual property. Support from our physician customers has been exceptional, with their patients delighted by the enhancements Axonics has brought to SNM, including longevity in the body and extending the recharge interval to once per month for one hour. We remain focused on increasing the awareness and expanding the adoption of SNM, which has the potential to significantly improve quality of life for millions of patients suffering from bladder and bowel dysfunction.”